CRISPR

A GLP-grade non-replicative Leishmania major parasite protects hamsters from lethal leishmaniasis infection, setting the stage for human clinical trials and the first potential vaccine for leishmaniasis.

Researchers employ CRISPR technology in a variety of creative ways to control the spread of vector-borne illnesses.

LIVE July 28th, 2021 at 2:30 PM ET
In this webinar, experts will discuss cytosine and adenosine base-editors to introduce point mutations in DNA strands without creating a breakpoint, and opportunities and considerations for using them.

From excising integrated viral sequences to modifying stem cells, CRISPR offers new possibilities for developing HIV treatments.

LIVE June 17th, 2021 at 2:30 PM ET
This webinar will discuss recent disease and drug discoveries enabled through screening CRISPR-modified stem cells.

The arguments over "first to invent" and ownership of CRISPR tech continue

Study demonstrates how changes in human genes can reduce SARS-CoV-2 infection

Jumpcode details how its CRISPRclean tech unites NGS and CRISPR/Cas editing

NIH grant will help researchers learn ways to counter drug resistance via gene editing